Roentgenographic findings during auranofin treatment.
Roentgenograms of hands and wrists from rheumatoid arthritis patients treated with auranofin for 12 and 24 months were scored for severity of erosive disease. Scores were analyzed by a method in which a calculated mean annual rate of erosion prior to treatment was compared with the annualized rate during therapy. The original films from a previous Myochrysine versus placebo study were reanalyzed in order to compare the results of different scoring methods and to provide an auranofin versus placebo comparison. Two readers found the rate of erosion during oral gold therapy to be less than that predicted by the analytical model. Interobserver differences in scoring were demonstrated. A breakdown of patient scores by duration of disease showed the greatest difference between scores observed during treatment with those predicted by the model in patients with early disease.
D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000000981:diagnostic imaging / Q000188:drug therapy*; D001310:Auranofin; D006051:Aurothioglucose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006046:Gold / Q000031:analogs & derivatives*; D006225:Hand / Q000000981:diagnostic imaging*; D006801:Humans; D011859:Radiography; D014953:Wrist / Q000000981:diagnostic imaging*
D000893:Anti-Inflammatory Agents; D006051:Aurothioglucose; D001310:Auranofin; D006046:Gold